{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:01:18Z","timestamp":1780293678541,"version":"3.54.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.106901","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:52:40Z","timestamp":1776804760000},"page":"106901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7109-2429","authenticated-orcid":false,"given":"A.","family":"Cigliola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-6380","authenticated-orcid":false,"given":"F.","family":"Rossari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-2338","authenticated-orcid":false,"given":"V.","family":"Tateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":false,"given":"C.","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-8513","authenticated-orcid":false,"given":"N.","family":"Dizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-0743","authenticated-orcid":false,"given":"M.","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9225-1795","authenticated-orcid":false,"given":"U.","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"N.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.esmoop.2026.106901_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106901_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.esmoop.2026.106901_bib3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106901_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106901_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2026.106901_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102379","article-title":"Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations","volume":"105","author":"Iacovelli","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"36","key":"10.1016\/j.esmoop.2026.106901_bib7","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.20.02295","article-title":"Optimized management of nivolumab and ipilimumab in advanced renal cell carcinoma: a response-based phase II study (OMNIVORE)","volume":"38","author":"McKay","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106901_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106901_bib9","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.3390\/cancers15123172","article-title":"Immune checkpoint inhibitor rechallenge in renal cell carcinoma: current evidence and future directions","volume":"15","author":"Sammarco","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10397","key":"10.1016\/j.esmoop.2026.106901_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"10460","key":"10.1016\/j.esmoop.2026.106901_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106901_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.28526","article-title":"Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC","volume":"7","author":"Sun","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106901_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70324","article-title":"Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2024","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106901_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009165","article-title":"Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect","volume":"12","author":"Lu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.106901_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/492920","article-title":"Modulation of immunity by antiangiogenic molecules in cancer","volume":"2012","author":"Terme","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106901_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/CJI.0b013e3181f4c208","article-title":"A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients","volume":"33","author":"Adotevi","year":"2010","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106901_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijc.25674","article-title":"Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients","volume":"129","author":"Desar","year":"2011","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106901_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.biopha.2014.07.002","article-title":"Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation","volume":"68","author":"Yuan","year":"2014","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106901_bib19","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-021-24343-x","article-title":"The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival","volume":"12","author":"Valpione","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106901_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","article-title":"T-cell repertoire diversity: friend or foe for protective antitumor response?","volume":"41","author":"Porciello","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106901_bib21","article-title":"Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106901_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106901_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.esmoop.2026.106901_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gore.2019.04.002","article-title":"Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: a retrospective study of the Memorial Sloan Kettering Cancer Center experience","volume":"28","author":"Rubinstein","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.esmoop.2026.106901_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115569","article-title":"Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: insights from a European delphi study","volume":"225","author":"Gr\u00fcnwald","year":"2025","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106901_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.12.002","article-title":"Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma","volume":"42","author":"Obeng-Kusi","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.esmoop.2026.106901_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3449660","article-title":"REchallenge of NIVOlumab (RENIVO) or nivolumab-ipilimumab in metastatic renal cell carcinoma: an ambispective multicenter study","volume":"2022","author":"Vauchier","year":"2022","journal-title":"J Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:12:46Z","timestamp":1780290766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926008434"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106901","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106901"}}